PT-141 (Bremelanotide) 10 mg

PT-141 (Bremelanotide) 10 mg — central melanocortin signalling, isolated
PT-141 is what remains when you strip the pigmentation activity away from Melanotan II and keep the central signalling. That deliberate narrowing is why it occupies its own place in melanocortin research.

What is PT-141 (Bremelanotide)?

Bremelanotide, known in research contexts as PT-141, is a cyclic heptapeptide and an active metabolite of Melanotan II. Structurally it differs by the absence of the C-terminal amide group, a change that substantially shifts its receptor profile away from peripheral pigmentary signalling and towards central melanocortin receptors, particularly MC4R and MC3R. Because it acts on central nervous system pathways rather than through vascular mechanisms, it is studied as a mechanistically distinct compound from vasoactive agents — a point frequently emphasised in the literature.

Research interest

• MC4R / MC3R pharmacology — used as a reference agonist in studies of central melanocortin receptor signalling.
• Central versus peripheral action — investigated by researchers distinguishing CNS-mediated from vascular or peripheral mechanisms.
• Neuroendocrine signalling — of interest to groups examining hypothalamic melanocortin circuits and their downstream outputs.
• Metabolite pharmacology — studied as a case in which an active metabolite exhibits a meaningfully different profile from its parent compound.
• Comparative melanocortin work — routinely benchmarked against MT-1 and MT-2 to map receptor subtype contributions.

As a cyclic peptide, PT-141's activity depends on ring integrity rather than sequence alone. Analytical verification per lot is essential where the research question concerns receptor subtype discrimination at fine resolution.

Specifications

• Content: 10 mg of active substance per vial
• Form: Lyophilised powder (vial)
• Purity: Pharmaceutical-grade, batch-tested and lot-traceable
• Presentation: Sealed, tamper-evident single vial
• Storage: -20 °C sealed; 2-8 °C short-term

Handling & storage

Store sealed lyophilised vials at -20 °C for long-term stability; short periods at 2-8 °C are generally tolerated during transit and handling. Keep vials sealed, protected from light and away from moisture and repeated temperature swings. Store the sealed vial frozen, dry and away from light. Allow it to equilibrate to ambient temperature before opening. Any laboratory reconstitution should use an appropriate sterile diluent under the facility's own validated method; keep the resulting solution refrigerated, light-protected and free of repeated freeze-thaw.

The Rogue standard

• Analytically verified — every lot tested for purity and identity, with traceable batch records.
• Sealed and authentic — European supply chain, no grey-market intermediaries, no relabelled stock.
• Built for repeatable work — stable lot quality so results are not confounded by material variance.
• Discreet, tracked delivery — fast dispatch across the EU in unbranded packaging.

For research purposes only. Not a medicinal product. Not for human or veterinary consumption. Intended for qualified laboratory research use only. No statement on this page is a medical claim, and no administration, dosing or protocol guidance is offered or implied.

Related: Peptides · CJC-1295 no DAC 5 mg · 5-amino-1MQ 50mg · GHK-Cu 100 mg